FEVERFEW

OTHER NAME(S):

Altamisa, Bachelor's Buttons, Chrysanthème Matricaire, Chrysanthemum parthenium, Chrysanthemum praealtum, Featerfoiul, Featherfew, Featherfoil, Flirtwort Midsummer Daisy, Grande Camomille, Leucanthemum parthenium, Matricaria, Matricaria eximia, Matricaria parthenium, Partenelle, Pyrèthre Doré, Pyrèthre Mousse, Pyrethrum parthenium, Santa Maria, Tanaceti Parthenii, Tanacetum Parthenium, Tanaisie Commune.<br/><br/>

Overview

Overview Information

Feverfew is a plant that is native to Asia Minor and the Balkans, but is now common throughout the world. Feverfew leaves are normally dried for use in medicine. Fresh leaves and extracts are also used.

People take feverfew by mouth for the prevention and treatment of migraine headaches.

People also take feverfew by mouth for fever, irregular menstrual periods, arthritis, a skin disorder called psoriasis, allergies, asthma, ringing in the ears (tinnitus), dizziness, and nausea and vomiting.

Some people take feverfew by mouth for difficulty getting pregnant or fathering a child (infertility). It is also taken by mouth for "tired blood" (anemia), cancer, common cold, earache, liver disease, prevention of miscarriage, muscular tension, bone disorders, swollen feet, diarrhea, upset stomach, and intestinal gas.

Feverfew is sometimes applied directly to the gums for toothaches or to the skin to kill germs. It is also applied to the skin for itching and to prevent insect bites.

Some people also use feverfew as a general stimulant and for intestinal parasites.

How does it work?

Feverfew leaves contain many different chemicals, including one called parthenolide. Parthenolide or other chemicals decrease factors in the body that might cause migraine headaches.

Uses

Uses & Effectiveness?

Possibly Effective for

  • Preventing migraine headache. Some research using different feverfew products (Mig-RL, Naturveda-Vitro-Bio Research Institute, Issoire, France; LipiGesic M, PuraMed BioScience, Inc., Schofield, WI; GelStat Migraine, GelStat Corporation) shows that taking feverfew by mouth can reduce the frequency of migraine headaches and reduce pain, nausea, vomiting, and sensitivity to light and noise when they do occur. Feverfew may be more effective in people with more frequent migraine attacks. But there are also studies that concluded that feverfew doesn't work for migraines. The difference in results may be explained by the differences in feverfew products that were tested. The Canadian government allows manufacturers of a certain feverfew formulation (containing 0.2% of a chemical called parthenolide) to claim that their product can be used to prevent migraines.

Possibly Ineffective for

Insufficient Evidence for

  • Itching (pruritus). Early research shows that applying a cream containing feverfew (Aveeno Ultra-Calming Cream, Johnson & Johnson) to the skin improves skin itching in people with a skin disease called prurigo nodularis.
  • Allergies.
  • Asthma.
  • Bone disorders.
  • Cancer.
  • Common cold.
  • Dizziness.
  • Earache.
  • Fever.
  • Intestinal parasites.
  • Liver disease.
  • Menstrual irregularities.
  • Miscarriage prevention.
  • Muscle tension.
  • Nausea.
  • Psoriasis.
  • Ringing in the ears.
  • Swollen feet.
  • Toothaches.
  • Upset stomach.
  • Vomiting.
  • Other conditions.
More evidence is needed to rate the effectiveness of feverfew for these uses.

Side Effects

Side Effects & Safety

Feverfew is LIKELY SAFE when taken by mouth appropriately in the short-term (up to four months). Side effects might include upset stomach, heartburn, diarrhea, constipation, bloating, flatulence, nausea, and vomiting. Other reported side effects include nervousness, dizziness, headache, trouble sleeping, joint stiffness, tiredness, menstrual changes, rash, pounding heart, and weight gain.

The safety of feverfew beyond 4 months' use has not been studied.

Feverfew is POSSIBLY UNSAFE when fresh leave are chewed. Chewing unprocessed feverfew leaves can cause mouth sores; swelling of the mouth, tongue, and lips; and loss of taste.

Special Precautions & Warnings:

Pregnancy and breast-feeding: Feverfew is POSSIBLY UNSAFE when taken by mouth during pregnancy. There is concern that it might cause early contractions and miscarriage. Don't use feverfew if you are pregnant. There is not enough reliable information about the safety of taking feverfew if you are breast feeding. Stay on the safe side and avoid use.

Bleeding disorders: Feverfew might slow blood clotting. In theory, taking feverfew could increase the risk of bleeding in some people. Until more is known, use feverfew cautiously if you have a bleeding disorder.

Allergy to ragweed and related plants: Feverfew may cause an allergic reaction in people who are sensitive to the Asteraceae/Compositae plant family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many others. If you have allergies, be sure to check with your healthcare provider before taking feverfew.

Surgery: Feverfew might slow blood clotting. It might cause bleeding during and after surgery. Stop taking feverfew at least 2 weeks before a scheduled surgery.

Interactions

Interactions?

Moderate Interaction

Be cautious with this combination

!
  • Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with FEVERFEW

    Some medications are changed and broken down by the liver.<br /><br /> Feverfew might decrease how quickly the liver breaks down some medications. Taking feverfew along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking feverfew, talk to your healthcare provider if you take any medications that are changed by the liver.<br /><br /> Some medications that are changed by the liver include amitriptyline (Elavil), haloperidol (Haldol), ondansetron (Zofran), propranolol (Inderal), theophylline (Theo-Dur, others), verapamil (Calan, Isoptin, others), and others.

  • Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) interacts with FEVERFEW

    Some medications are changed and broken down by the liver.<br /><br /> Feverfew might decrease how quickly the liver breaks down some medications. Taking feverfew along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking feverfew, talk to your healthcare provider if you take any medications that are changed by the liver.<br /><br /> Some medications that are changed by the liver include omeprazole (Prilosec), lansoprazole (Prevacid), and pantoprazole (Protonix); diazepam (Valium); carisoprodol (Soma); nelfinavir (Viracept); and others.

  • Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with FEVERFEW

    Some medications are changed and broken down by the liver.<br /><br /> Feverfew might decrease how quickly the liver breaks down some medications. Taking feverfew along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking feverfew, talk to your healthcare provider if you take any medications that are changed by the liver.<br /><br /> Some medications that are changed by the liver include diclofenac (Cataflam, Voltaren), ibuprofen (Motrin), meloxicam (Mobic), and piroxicam (Feldene); celecoxib (Celebrex); amitriptyline (Elavil); warfarin (Coumadin); glipizide (Glucotrol); losartan (Cozaar); and others.

  • Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with FEVERFEW

    Some medications are changed and broken down by the liver.<br /><br /> Feverfew might decrease how quickly the liver breaks down some medications. Taking feverfew along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking feverfew, talk to your healthcare provider if you are taking any medications that are changed by the liver.<br /><br /> Some medications changed by the liver include lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), triazolam (Halcion), and many others.

  • Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with FEVERFEW

    Feverfew might slow blood clotting. Taking feverfew along with medications that also slow clotting might increase the chances of bruising and bleeding.<br /><br /> Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.

Dosing

Dosing

The following doses have been studied in scientific research:

BY MOUTH:

  • For migraine headaches: 50-150 mg of feverfew powder taken once daily for up to 4 months has been used. A dose of 2.08-18.75 mg of a carbon dioxide extract of feverfew (MIG-99, Schaper & Brümmer GmbH & Co, Salzgitter, Germany) taken three times daily for 3 to 4 months has been used. Mig-RL (Naturveda-Vitro-Bio Research Institute, Issoire, France), a combination of 300 mg of feverfew and 300 mg of white willow, taken twice daily for 3 months has been used. Specific combination products containing feverfew and ginger (GelStat Migraine, GelStat Corporation; LipiGesic M, PuraMed BioScience, Inc., Schofield, WI) have been used to treat migraines. Two 2-mL doses have been given under the tongue 5 minutes apart. Each dose has been held under the tongue for 60 seconds before swallowing. A second and possibly third treatment have been used one hour and possibly 24 hours later if the migraine headache pain continues.

View References

REFERENCES:

  • Awang DV. Parthenocide: the demise of a facile theory of feverfew activity. J Herbs Spices Med Plants 1998;5(4):95-98.
  • Christensen, L. P., Jakobsen, H. B., Paulsen, E., Hodal, L., and Andersen, K. E. Airborne Compositae dermatitis: monoterpenes and no parthenolide are released from flowering Tanacetum parthenium (feverfew) plants. Arch Dermatol Res 1999;291(7-8):425-431. View abstract.
  • Czyz, M., Lesiak-Mieczkowska, K., Koprowska, K., Szulawska-Mroczek, A., and Wozniak, M. Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br.J.Pharmacol. 2010;160(5):1144-1157. View abstract.
  • De Weerdt, C. J., Bootsma, H. P., and Hendriks, H. Herbal medicines in migraine prevention Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225-230. View abstract.
  • DeWeerdt CJ, Bootsman H, and Hendricks H. Herbal medicines in migraine prevention. Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomed 1996;3(3):225-230.
  • Gromek, D., Kisiel, W., Stojakowska, A., and Kohlmunzer, S. Attempts of chemical standardizing of Chrysanthemum parthenium as a prospective antimigraine drug. Pol.J.Pharmacol.Pharm. 1991;43(3):213-217. View abstract.
  • Hayes, N. A. and Foreman, J. C. The activity of compounds extracted from feverfew on histamine release from rat mast cells. J Pharm Pharmacol 1987;39(6):466-470. View abstract.
  • Kemper, K. J. and Breuner, C. C. Complementary, holistic, and integrative medicine: headaches. Pediatr.Rev. 2010;31(2):e17-e23. View abstract.
  • Kuritzky A, Elhacham Y, Yerushalmi Z, and et al. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994;44(Suppl 2):A201.
  • Loder, E., Burch, R., and Rizzoli, P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012;52(6):930-945. View abstract.
  • Mauskop, A. Nonmedication, alternative, and complementary treatments for migraine. Continuum (Minneap.Minn.) 2012;18(4):796-806. View abstract.
  • Modi, S. and Lowder, D. M. Medications for migraine prophylaxis. Am Fam.Physician 1-1-2006;73(1):72-78. View abstract.
  • Palevitch D, Earon G, and Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997;11(7):508-511.
  • Pfaffenrath V, Fischer M, Friede M, and et al. Clinical dose-response study for the investigation of efficacy and tolerability of Tanacetum parthenium in migraine prophylaxis. Deutscher Schmerzkongress; October 20-24, 1999, Munich, Germany. 1999;
  • Silberstein, S. D. Preventive treatment of headaches. Curr Opin Neurol. 2005;18(3):289-292. View abstract.
  • Sun-Edelstein, C. and Mauskop, A. Foods and supplements in the management of migraine headaches. Clin J Pain 2009;25(5):446-452. View abstract.
  • Waller, P. C. and Ramsay, L. E. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 10-19-1985;291(6502):1128. View abstract.
  • Awang DV. Parthenocide: demise of a facile theory of feverfew activity. J Herbs Spices Med Plants 1998;5:95-8.
  • Awang DVC. Prescribing therapeutic feverfew (Tancetum pathrnium (L.) Schultz Bip., syn. Chrysanthemumparthenium (L.) Bernh). Int Med 1998;1:11-3.
  • Barsby R, Salan U, Knight DW, Hoult JR. Irreversible inhibition of vascular reactivity by feverfew. Lancet 1991;338:1015. View abstract.
  • Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta. J Pharm Pharmacol 1992;44:737-40. View abstract.
  • Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;2:776. View abstract.
  • Brun J, Claustrat B, Saddier P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995;15:136-9. View abstract.
  • Cady RK, Goldstein J, Nett R, et al. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic M) in the treatment of migraine. Headache 2011;51:1078-86. View abstract.
  • Cady RK, Schreiber CP, Beach ME, et al. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. Med Sci Monit. 2005;11:I65-69. View abstract.
  • Collier HO, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet 1980;2:922-3. View abstract.
  • de Weerdt GJ, Bootsman HPR, Hendriks H. Herbal medicines in migraine prevention. Randomized double-blind, placebo-controlled, crossover trial of a feverfew preparation. Phytomedicine 1996;3:225-30.
  • Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005;25:1031-41. View abstract.
  • Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr 2000;3:509-14. View abstract.
  • Ferro EC, Biagini AP, da Silva ÍE, Silva ML, Silva JR. The combined effect of acupuncture and Tanacetum parthenium on quality of life in women with headache: randomised study. Acupunct Med. 2012 Dec;30(4):252-7. View abstract.
  • Foster S. Feverfew, Tanacetum parthenium, botanical series #310. Austin, TX: Am Botanical Council, 1996.
  • Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J Pharm Pharmacol 1990;42:553-7. View abstract.
  • Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J Pharm Pharmacol 1987;39:459-65. View abstract.
  • Heptinstall S, Groenewegen WA, Spangenberg P, Losche W. Inhibition of platelet behaviour by feverfew: a mechanism of action involving sulphydryl groups. Folia Haematol Int Mag Klin Morphol Blutforsch 1988;115:447-9. View abstract.
  • Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1985;1:1071-4. View abstract.
  • Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346-53. View abstract.
  • Hwang D, Fischer NH, Jang BC, et al. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996;226:810-8.. View abstract.
  • Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. J Ethnopharmacol 1999;68:251-9. View abstract.
  • Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 1985;291:569-73. View abstract.
  • Kuritzky A, Elhacham Y, Yerushalmi Z, et al. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994;44(Suppl 2):A201. (Abstract 293P)
  • Lamminpaa A, Estlander T, Jolanki R, Kanerva L. Occupational allergic contact dermatitis caused by decorative plants. Contact Dermatitis 1996;34:330-5. View abstract.
  • Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004;44:885-90. View abstract.
  • Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med 1982;8:653-60. View abstract.
  • Makheja AN, Bailey JM. The active principle in feverfew. Lancet 1981;2:1054. View abstract.
  • McCrory DC, Matchar DB, Gray RN, et al. Evidence-based guidelines for migraine headache: overview of program description and methodology. US Headache Consortium, April 2000. Available at: www.aan.com/cgi-bin/whatsnewlink.pl?loc=/public/practiceguidelines.
  • Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997;350:1598-9. View abstract.
  • Murphy JJ, Heptinstall S, Mitchell JR. Randomized, double-blind, placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189-92. View abstract.
  • Palevitch D, Earon G, Carasso R. Feverfew (tanacetum parthenium) as a prophylactic treatment for migraine- a double-blind, placebo-controlled study. Phytotherapy Res 1997;11:508-11.
  • Pareek A, Suthar M, Rathore G, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev. 2011;5(9):103-110. View abstract.
  • Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double-blind, placebo-controlled study. Ann Rheum Dis 1989;48:547-9. View abstract.
  • Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22:523-32. View abstract.
  • Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004;(1):CD002286. View abstract.
  • Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2000;3:CD002286. View abstract.
  • Prusinski A, Durko A, and Niczyporuk-Turek A. [Feverfew as a prophylactic treatment of migraine]. Neurol.Neurochir.Pol. 1999;33 Suppl 5:89-95. View abstract.
  • Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 1988;40:743-5. View abstract.
  • Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 1999;65:126-9. View abstract.
  • Saraceno R, Chiricozzi A, Nistico SP, et al. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J.Dermatolog.Treat. 2010;21:363-66. View abstract.
  • Shrivastava R, Pechadre JC, and John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin Drug Investig. 2006;26:287-96. View abstract.
  • Sil'vestrov VP, Kinitin AV, and Chesnokova, IV. [Immunological and metabolic disorders and the means for their correction in patients with chronic bronchitis]. Ter.Arkh. 1991;63:7-11. View abstract.
  • Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992;43:2313-20. View abstract.
  • Sur R, Martin K, Liebel F, et al. Anti-inflammatory activity of parthenolide-depleted Feverfew (Tanacetum parthenium). Inflammopharmacology. 2009;17:42-9. View abstract.
  • Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;18:2273-81. View abstract.
  • Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998;18:704-8. View abstract.
  • Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015 Apr 20;4:CD002286. [Epub ahead of print] View abstract.
  • Williams CA, Harborne JB, Geiger H, Hoult JR. The flavonoids of Tanacetum parthenium and T. vulgare and their anti-inflammatory properties. Phytochemistry 1999;51:417-23. View abstract.
  • Williams CA, Hoult JR, Harborne JB, et al. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry 1995;38:267-70. View abstract.
  • Wong HC. Is feverfew a pharmacologic agent? CMAJ 1999;160:21-2. View abstract.

More Resources for FEVERFEW

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.